Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

Cogent Biosciences, Inc.

COGT

Filing: SEC 10-Q
Period: Three months ended March 31, 2026
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of Cogent Biosciences, Inc.. A complete text table follows the diagram.

Cogent Biosciences Pipeline Flow

An emerging therapeutics platform is still in development rather than commercial revenue.

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0001193125-26-205170
Filed: Date not recorded
Reviewed: Date not recorded
Status: Individual filing review complete

How to read these figures

Labels and displayed flow values are reported filing values or exact disclosed subtotals.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

The filing states that Cogent has no approved products and no product revenue. This indexed view avoids fabricating a revenue split.

View accessible tables

Financial categories · Three months ended March 31, 2026 · Millions of USD
Category	Stage	Value	Notes
Cogent Biosciences revenue	1	$1M	$1.000M reported quarterly revenue
Biopharmaceutical pipeline	2	$1M	Indexed review view

Financial flows · Millions of USD
From	To	Value
Cogent Biosciences revenue	Biopharmaceutical pipeline	$1M